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T cells play a pathogenic role in many autoim-
mune diseases, including rheumatoid arthritis, 
type 1 diabetes, and multiple sclerosis (MS). 
MS and the mouse model, experimental auto-
immune encephalomyelitis (EAE), are chronic 
infl   ammatory diseases of the central nervous 
system (1), which until recently were assumed 
to be mediated by Th1 cells (2). However, 
IFN-γ KO mice have an increased susceptibil-
ity to EAE (3), and disease is exacerbated in 
mice defi  cient in the Th1-polarizing cytokine 
IL-12 (4). In contrast, induction of disease is 
blocked in mice defi  cient in the novel IL-12 
family member, IL-23 (4), which promotes the 
diff  erentiation of IL-17–producing (ThIL-17) 
cells (5, 6). The demonstration that adoptive 
transfer of autoantigen-specifi  c ThIL-17 cells, 
but not Th1 cells, induced EAE (6), as well as 
studies in collagen-induced arthritis (7), has estab-
lished a defi  nitive pathogenic role for these cells 
in T cell–mediated autoimmune diseases.
Recent reports have demonstrated that 
ThIL-17 cells are a distinct subtype from Th1 
and Th2 cells and do not share a precursor 
  intermediate (8, 9). Indeed, their diff  erentiation 
process is inhibited by the signature Th1 and 
Th2 cytokines, IFN-γ and IL-4 (8). IL-23 can 
act on eff  ector and memory CD4+ T cells to 
induce T cell proliferation and IL-17 secretion 
(5), but it can also promote the diff  erentiation 
of naive T cells into ThIL-17 cells (8, 9). ThIL-
17 cells may function in autoimmunity by pro-
moting the induction of IL-1β and TNF-α. It 
has been shown that IL-1β and TNF-α can 
mediate infl  ammatory pathology in many auto-
immune diseases, and antibodies or receptor 
antagonists of these infl  ammatory cytokines are 
eff  ective therapeutics. In rheumatoid arthritis, 
IL-17 is thought to play a major role upstream 
of IL-1 (10, 11) in promoting autoimmune 
joint destruction. Furthermore, studies with IL-
1RI−/− mice  have established a role for IL-1 in 
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the induction of EAE   (12). In addition, IL-1β is present in 
MS lesions and families with a high IL-1β to IL-1 receptor 
antagonist (IL-1Ra) production ratio are at a greater risk of 
having a relative with relapse-onset MS than those with a low 
ratio (13). However, the precise role of IL-1 in the pathogen-
esis of EAE is unclear.
We demonstrate that IL-23 alone is a poor stimulus for 
T cell IL-17 production and that IL-1 is essential for its induc-
tion. Immunization with foreign or self-antigens and a Toll-
like receptor ligand or CFA demonstrated that IL-1 plays a 
vital and selective role in promoting antigen-specifi  c ThIL-
17 cells in vivo. Furthermore, a failure to induce EAE in 
IL-1RI−/− mice was associated with a failure to generate 
ThIL-17 cells. IL-1 acted directly on T cells in synergy with 
IL-23 to promote IL-17 secretion. TNF-α also synergized 
with IL-23 to induce IL-17, but this was dependant on IL-1. 
Our fi  ndings demonstrate a central role for IL-1 upstream of 
IL-17 in promoting autoimmunity in EAE by driving the 
diff  erentiation of pathogenic ThIL-17 cells.
RESULTS AND DISCUSSION
IL-1RI is required for the induction of ThIL-17 cells
In a study on the role of IL-1RI in the adjuvant eff  ect of 
the Toll-like receptor agonist LPS, we discovered that IL-1 is 
Figure 1.  IL-1RI is required for induction or activation of antigen-
specifi  c ThIL-17 T cells. (A) C57BL/6 or IL-1RI−/− mice were immunized 
s.c. with 10 μg KLH either alone or with 10 μg LPS. Inguinal lymph nodes 
were harvested after 7 d and cells were restimulated with medium or 2, 
10, or 50 μg/ml KLH. (B) Lymph node cells were restimulated with me-
dium or 20 ng/ml PMA and 1 μg/ml anti-CD3. Supernatants were col-
lected after 3 d, and IL-4, IL-10, IL-17, and IFN-γ concentrations were 
determined by ELISA. C57BL/6 versus IL-1RI−/−: *, P < 0.05; **, P < 0.01; 
***, P < 0.001.
Figure 2.  The induction of EAE and autoantigen-specifi  c ThIL-17 
cells is dependent on functional IL-1RI. C57BL/6 or IL-1RI
−/− mice 
were injected with 150 μg MOG in 200 μl CFA and 500 ng PT followed 
2 d later with a second dose of PT. Mice were observed for clinical symp-
toms of EAE daily for 48 d. A separate group of mice were killed on d 21, 
and spleen cells were restimulated with MOG peptide. After 3 d, super-
natants were collected and cytokine concentrations were determined 
by ELISA. Cell proliferation was determined on day 4 of culture by 
[3H]thymidine incorporation. (A) Disease scores (n = 15) ± SD. (B) Antigen-
specifi  c cytokine production and proliferation. C57BL/6 versus IL-1RI−/−: 
*, P < 0.05; **, P < 0.01; ***, P < 0.001. (C) IL-1RI−/− mice (n = 7) were 
injected with MOG in CFA followed by PT as described above or with 
MOG-specifi  c T cells (9 × 106 cells/mouse) generated from the spleens 
of C57BL/6 mice with EAE. Disease scores (n = 5) ± SD.JEM VOL. 203, July 10, 2006  1687
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selectively required for induction of ThIL-17 cells. Parenteral im-
munization of C57BL/6 mice with KLH in the presence of LPS 
induced antigen-specifi  c T cells that secreted IFN-γ, IL-10, and 
IL-17, whereas immunization with KLH in the absence of ad-
juvant induced little or no antigen-specifi  c cytokine production 
(Fig. 1 A). Immunization of IL-1RI−/− mice with KLH and 
LPS also induced antigen-specifi  c IFN-γ and IL-10 production. 
However, antigen-specifi  c IL-17 production was signifi  cantly 
lower in IL-1RI−/− than in wild-type C57BL/6 mice. Antigen-
specifi  c proliferation was not signifi  cantly diff  erent between the 
groups (not depicted). IL-17 concentrations induced by PMA 
and anti-CD3 were also signifi   cantly lower in cells from 
IL-1RI−/− mice (Fig. 1 B). Thus, IL-1 is selectively required for 
antigen or anti-CD3 and PMA-induced IL-17 production.
IL-1RI–defi  cient mice are resistant to EAE, 
and this correlates with reduced autoantigen-specifi  c 
IL-17 production
We next examined the possibility that IL-1 may function in 
the pathology of EAE by promoting pathogenic autoantigen-
specifi  c ThIL-17 cells. Wild-type C57BL/6 mice developed 
severe EAE after immunization with myelin oligodendrocyte 
glycoprotein (MOG) and CFA. In contrast, the incidence of 
EAE (2/15 IL-1RI−/− vs. 13/15 in C57BL/6) was consider-
ably lower in IL-1RI−/− mice (Fig. 2 A). This is consistent 
with studies indicating an important role for IL-1 in EAE 
(12, 14). However, we demonstrate that the resistance of IL-
1RI−/− mice to the development of EAE correlates with a 
specifi   c defect in activating autoantigen-specifi  c  ThIL-17 
cells (Fig. 2 B). MOG-specifi  c IL-17 production was selec-
tively reduced in IL-1RI−/− mice in comparison with wild-
type mice (Fig. 2 B). MOG-specifi  c  proliferation  and 
secretion of IL-6, IL-10, and TNF-α were comparable in IL-
1RI−/− and wild-type mice. Production of IFN-γ was re-
duced, but to a modest extent (twofold reduction compared 
with a 22-fold reduction in IL-17 production).
We examined the ability of MOG-specifi  c T cells from 
wild-type mice to induce EAE in IL-1RI−/− mice and com-
pared this with standard EAE induction. Transfer of a MOG-
specifi  c T cell line from C57BL/6 mice with advanced EAE 
into IL-1RI−/− mice induced EAE in fi  ve out of fi  ve mice, 
whereas mice injected directly with MOG and CFA did not 
develop disease (Fig. 2 C), demonstrating that IL-1RI is dis-
pensable in the development of EAE after induction of the 
autoantigen-specifi  c ThIL-17 T cells. Our data support fi  nd-
ings that neuroantigen-specifi  c ThIL-17 cells can transfer EAE 
(6) and suggest that the major role of IL-1 in the development 
Figure 3.  IL-1 synergizes with IL-23 to promote IL-17 production 
by spleen cells and purifi  ed CD4+ and CD8+ T cells. (A) Spleen cells 
(106 cells/ml) from C57BL/6 or IL-1RI−/− mice were cultured with 100 pg/ml 
IL-23 alone or together with 1 ng/ml IL-1α, and supernatants were col-
lected after 3 d for analysis of IL-17 and IFN-γ by ELISA. C57BL/6 versus 
IL-1RI−/−: *, P < 0.05; **, P < 0.01; ***, P < 0.001. IL-1α plus IL-23 versus 
IL-23; #, P < 0.001. (B) Spleen cells (2.25 × 106 cells/ml) from C57BL/6 
mice were cultured for 48 h with medium or cytokines and for the last 4 h 
in the presence of 10 μg/ml brefeldin A. Intracellular staining for IL-17 
and IFN-γ was performed. Percentages refer to IL-17 production by gated 
CD3+ T cells. Splenic CD4+ (C) and CD8+ (D) T cells (5 × 10
5cells/ml) from 
C57BL/6 mice were incubated with 10 U/ml IL-2 and 1 μg/ml anti-CD3 
antibody alone or together with 0.1–1 ng/ml IL-23 and/or 1 ng/ml IL-1α 
or IL-1β. IL-17 concentrations were measured by ELISA in supernatants 
collected after 3 d. IL-23 plus IL-1 versus IL-23 only: *, P < 0.05; 
**, P < 0.01; ***, P < 0.001.1688  IL-1 DRIVES PATHOGENIC T CELLS IN AUTOIMMUNITY | Sutton et al. 
of EAE is in promoting pathogenic ThIL-17 cells. The clinical 
symptoms in EAE are ameliorated by blocking IL-17 (9, 15), 
and injection of anti–IL-17 delays the onset of disease and 
prevents the characteristic mononuclear cell infi  ltrate in spinal 
cord white matter (9). Our data place IL-1 upstream of IL-17 
and suggest that the effi   cacy of blocking IL-1 as a therapy for 
EAE may refl  ect a failure to activate ThIL-17 cells.
IL-1 synergizes with IL-23 to promote T cell 
IL-17 production
Because our data pointed to a selective eff  ect of IL-1 in pro-
moting ThIL-17 cells, we determined whether IL-1 directly 
induced IL-17 secretion by T cells in vitro. Stimulation with 
rIL-23 induced IL-17 production by spleen cells from 
C57BL/6 but not from IL-1RI−/−mice (Fig. 3 A). How-
ever, production of IL-17 in response to IL-23 alone was 
relatively low. Furthermore, IL-1 alone did not induce IL-17 
secretion by spleen cells but signifi  cantly  augmented 
IL-23–induced IL-17 production. Intracellular cytokine 
staining revealed that IL-17 was produced by CD3+ T cells 
(Fig. 3 B). Furthermore, the addition of anti–IFN-γ in-
creased the frequency of IL-17–secreting T cells after stimu-
lation with IL-1 and IL-23, consistent with a negative eff  ect 
of IFN-γ on IL-17 production (9).
Figure 4.  IL-1 and IL-23 promote IL-17 production in the absence 
of TCR stimulation via stimulation of PI3K, NF-𝗋B, and PKC𝗉. 
(A) Splenic CD3+ cells (5 × 105 cells/ml) from C57BL/6 mice were incubated 
with 10 ng/ml IL-1β, 10 ng/ml IL-23, IL-1 and IL-23, or medium only in 
the presence or absence of anti-CD3, and supernatants were collected at 
12, 24, 48, or 72 h for analysis by ELISA. (B) Splenic CD3+ cells from 
C57BL/6 mice were incubated with 1 μg/ml anti-CD3 for 2 h before stim-
ulation with IL-1, IL-23, IL-1 and IL-23, or medium. IL-17 mRNA expres-
sion was evaluated by real-time PCR 48 h after stimulation, and the data 
represent the fold change for IL-17 mRNA in relation to 18S rRNA. IL-23 
plus IL-1 versus IL-23 only: *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
(C) CD3+ cells (5 × 105 cells/ml) were stimulated with medium (control) 
or with IL-23, IL-1, or IL-23 and IL-1 with or without anti-CD3 in the 
presence or absence of (30-min pretreatment) LY294002 (PI3K inhibitor at 
20 and 40 μM), BAY 11-7082 (NF-κB inhibitor at 4 and 8 μM), rottlerin 
(novel PKC inhibitor at 10 and 100 μM), UO126 (ERK inhibitor at 5 μM), 
or SB203580 (p38 inhibitor at 5 μM). Supernatants were collected 3 d 
later for analysis of IL-17 production by ELISA. IL-23 plus IL-1 versus 
IL-23 plus IL-1 plus inhibitor: *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
(D) CD3+ cells were incubated with medium only or with IL-1, IL-23, or IL-1 
and IL-23. Cell lysates were analyzed by Western blotting with antibodies 
specifi  c for phosphorylated Akt and IκB-α or β-actin as a loading control.JEM VOL. 203, July 10, 2006  1689
BRIEF DEFINITIVE REPORT
To determine whether the synergistic eff  ect of IL-1 on 
IL-23–induced IL-17 production was mediated directly on T 
cells or required accessory cells, we assessed the eff  ects of IL-1 
and IL-23 on purifi  ed T cells. CD4+ and CD8+ T cells from 
C57BL/6 mice were stimulated with IL-23 in the presence 
or absence of IL-1. IL-23 at concentrations of up to 1 ng/ml 
did not induce signifi  cant IL-17 production (Fig. 3 C). How-
ever, the addition of IL-1α or IL-1β resulted in a dramatic 
synergistic eff  ect with IL-23 in promoting IL-17 secretion. 
Both CD4+ and CD8+ T cells have been implicated in the 
pathology of MS (16) and EAE, and ThIL-17 T cells have 
been shown to induce EAE (6). Collectively with our data, 
these fi  ndings suggest that the requirement for IL-1RI to 
promote ThIL-17 cells and EAE refl  ects the need for synergy 
between IL-1 and IL-23 to induce IL-17 production.
To address whether the eff  ects of IL-23 and IL-1 in-
volved amplifi  cation of a TCR-activated pathway, we ex-
amined the eff   ects of IL-1 and IL-23 in the presence or 
absence of anti-CD3. IL-1– and IL-23–induced IL-17 pro-
duction was retained in the absence of anti-CD3 (Fig. 4 A). 
Recent studies have indicated that IL-23 acts by promoting 
the survival and expansion of ThIL-17 T cells (17). Analysis 
of IL-17 mRNA by real-time PCR revealed that IL-23 or 
IL-1 and IL-23, but not IL-1 alone, induced potent IL-17 
gene transcription (Fig. 4 B). Therefore, our data suggest that 
IL-23 is vital for induction of IL-17 mRNA expression. The 
recently documented ability of IL-6 and TGF-β to promote 
the diff  erentiation of ThIL-17 cells (17–19) may be depen-
dant on IL-1. We have found that IL-6 can synergize with 
IL-23 to promote IL-17 production, but this eff  ect was abro-
gated in cells from IL-1RI−/− mice (not depicted). Alterna-
tively, IL-1 and IL-23 may act independently of IL-6 and 
TGF-β to promote IL-17 production from T cells. How-
ever, the relative roles of IL-23, IL-6, TGF-β, and IL-1 in 
the diff  erentiation and survival of ThIL-17 cells require fur-
ther investigation.
Our data suggest that in addition to roles for IL-23, as 
well as CD28 and ICOS costimulation (9), in promoting the 
diff  erentiation of naive T cells into ThIL-17 cells, there is an 
additional and central requirement for IL-1.
Signaling pathways involved in IL-1– and IL-23–induced 
IL-17 production
Using specifi  c inhibitors of intracellular signaling pathways, 
we found that novel isoforms of protein kinase C (PKC), 
NF-κB, and PI3K are essential for IL-1 and IL-23 to pro-
mote IL-17 production by T cells (Fig. 4 C). These inhibitors 
completely blocked IL-1– and IL-23–induced IL-17 produc-
tion, which was observed in the presence or absence of TCR 
stimulation, indicating that the cytokines can activate signal-
ing pathways that directly promote IL-17 production.
PKCθ-defi  cient mice are resistant to EAE and this corre-
lates with reduced IL-17 in the central nervous systems of 
these mice (20). Our data support an important role for PKCθ 
(21) in IL-1– and IL-23–mediated induction of T cell IL-17 
production. We also demonstrate that PI3K and NF-κB are 
important in the induction of IL-17 (22) and that phosphory-
lation of Akt (a readout for PI3K activation) and IκB-α were 
induced independently by IL-1 and IL-23 (Fig. 4 D). It was 
reported that MAP kinase pathways are involved in IL-17 
transcriptional regulation in human T cells (23). We demon-
strate that in murine cells, inhibitors of ERK (UO126) and 
p38 (SB203580) did not inhibit IL-17 and, notably, ERK in-
hibition enhanced IL-17 production (Fig. 4 C). However, in 
the absence of TCR stimulation, inhibition of p38 reduced 
IL-17 production in response to IL-1 and IL-23.
TNF-𝗂 enhances IL-23–induced IL-17 
by an IL-1–dependent mechanism
In addition to IL-1, TNF-α has been shown to play a major 
role in the infl  ammatory pathology in T cell–mediated auto-
immune diseases and other chronic infl  ammatory conditions. 
Drugs targeting either IL-1 or TNF-α are eff  ective therapeu-
tics for these diseases. It has been assumed that TNF-α and 
IL-1 mediate infl  ammatory reactions downstream of the ef-
fects of T cells. However, the spontaneous arthritis that de-
velops in IL-1Ra−/− mice does not occur in T cell–defi  cient 
mice (24) or mice defi  cient in IL-17 (25), whereas IL-17 is 
enhanced in IL-1Ra−/− mice (25). We found that TNF-α 
alone did not induce IL-17 production by spleen cells but did 
synergize with IL-23 to promote IL-17 production (Fig. 5). 
This eff  ect was dependent on IL-1, which is consistent with 
reports that TNF-α can promote IL-1 production and stro-
mal cell IL-1RI expression (26) and that IL-1 was inhibited 
by treatment of psoriasis patients with a soluble TNF receptor 
(27). We found that TNF-α, but not IL-1 or IL-23, increased 
Figure 5.  TNF-𝗂 promotes IL-23–induced IL-17 production in an 
IL-1–dependent manner. Spleen cells (106 cells/ml) from C57BL/6 or IL-
1RI−/− were cultured with 1 ng/ml IL-23, 0.01–1 ng/ml TNF-α, 0.01–1 ng/ml 
IL-23 and TNF-α, medium, or PMA and anti-CD3. Supernatants were col-
lected after 3 d for analysis of IL-17 and IFN-γ production by ELISA. 
C57BL/6 versus IL-1RI−/−: *, P < 0.05; **, P < 0.01; ***, P < 0.001. TNF-α 
plus IL-23 versus IL-23: #, P < 0.05; ##, P < 0.01; ###, P < 0.001.1690  IL-1 DRIVES PATHOGENIC T CELLS IN AUTOIMMUNITY | Sutton et al. 
expression of IL-1RI on both CD4+ and CD8+ T cells (not 
depicted), which may enhance their responsiveness to IL-1.
Because there are complex cytokine networks operating 
at sites of infl  ammation, several cytokines, including IL-23, 
IL-1, and TNF-α, may contribute to amplify IL-17 produc-
tion. For example, IL-17 can synergize with TNF-α and IL-1 
to promote infl  ammatory gene expression (28). Our demon-
stration that IL-1 acts upstream of IL-17 in EAE, combined 
with fi  ndings that IL-17 can promote IL-1, indicates that 
there may be a “vicious circle” with IL-1 and IL-17 promot-
ing each other and amplifying the autoimmune response.
Our fi  ndings provide further evidence for a role of innate 
immune responses in directing adaptive immunity. Specifi  -
cally, in addition to the established proinfl  ammatory role of 
IL-1, our fi  ndings reveal a hitherto unrecognized regulatory 
role for IL-1α and IL-1β in selectively promoting pathogenic 
ThIL-17 cells that mediate autoimmunity.
MATERIALS AND METHODS
Mice. C57BL/6 and IL-1RI−/− mice were obtained from Harlan Ltd. and 
bred at Trinity College Dublin under specifi  c pathogen-free conditions.   
Mice were maintained according to the regulations of the European Union 
and the Irish Department of Health.
Immunization experiments. Mice were immunized s.c. in the fl  ank with 
KLH (10 μg per mouse; endotoxin-free; Calbiochem) alone or together with 
LPS (10 μg per mouse; Escherichia coli, serotype R515; Qbiogene), or with PBS. 
Mice were killed after 7 d and inguinal lymph nodes were removed.
Induction and assessment of EAE. C57BL/6 and IL-1RI−/− mice were 
immunized s.c. with 150 μg MOG peptide 35-55 (Cambridge BioSciences) 
emulsifi  ed in CFA supplemented with 5 mg/ml killed Mycobacterium tubercu-
losis (Chondrex). For the adoptive transfer studies, EAE was induced in 
C57BL/6 mice and when mice reached an average disease score of 4, spleens 
were harvested and cultured with 16 μg/ml MOG, 10 ng/ml IL-1, and 
10 ng/ml IL-23 for 3 d. Cells were washed and injected i.v. (9 × 106 per 
mouse) into IL-1RI−/− mice. Mice were injected i.p. with 500 ng pertussis 
toxin (PT; Sigma-Aldrich) on days 0 and 2. From day 2, mice were observed 
daily for signs of clinical disease. Disease severity was recorded as follows: 
grade 0, normal; grade 1, limp tail; grade 2, wobbly gait; grade 3, hind limb 
weakness; grade 4, hind limb paralysis; and grade 5, tetraparalysis/death.
Antigen-specifi  c proliferation and cytokine production. Lymph node 
cells (106 cells/ml) were stimulated with 2–50 μg/ml KLH, 20 ng/ml PMA 
(Sigma-Genosys), and 1 μg/ml anti–mouse CD3 (BD Biosciences), or me-
dium only. Alternatively, spleen cells (2 × 106 cells/ml) from mice with EAE 
were cultured with MOG (4 or 20 μg/ml), or medium only. Supernatants 
were collected after 72 h and cytokine concentrations were determined by 
ELISA using antibody pairs specifi  c for IL-4, IFN-γ, IL-6 (BD Biosciences), 
IL-17, TNF-α, or IL-10 (Duo-Set; R&D Systems.). On day 4, 1 μCi/well 
[3H]thymidine (GE Healthcare) was added and the cells were cultured for an 
additional 6 h, after which cells were harvested and proliferation was assessed 
by [3H]thymidine incorporation (1450 Microbeta; PerkinElmer).
T cell purifi  cation. Mouse T cell CD4 and CD8 subset column kits (R&D 
Systems) were used to purify CD4+ and CD8+ cells from the spleens of 
C57BL/6 mice. T cell purity was routinely >95%. T cells and spleen cells 
were incubated with IL-1α, IL-1β, TNF-α, and IL-23 (endotoxin content 
was <1 EU/μg protein in all cases; R&D Systems) alone or in combination. 
In the studies on intracellular signaling pathways, all inhibitors were obtained 
from Calbiochem. For experiments on purifi  ed T cells, IL-2 (Hoff  man-La 
Roche Inc.) and anti-CD3 were also included except where stated.
Intracellular cytokine staining. Spleen cells from C57BL/6 mice were 
incubated for 72 h with medium or cytokines in the presence of 10 μg/ml 
brefeldin A (for the last 4 h) before extracellular staining with anti-CD3. 
Cells were washed, blocked with 1 μg/ml of Fcγ blocker (BD Biosciences), 
fi  xed, permeabilized (Fix and Perm cell permeabilization kit; Caltag), and 
stained with anti–IL-17, anti–IFN-γ antibody, or the appropriate isotype 
control. Flow cytometric analysis was performed using a FACSCalibur fl  ow 
cytometer (Becton Dickinson).
Western blotting. CD3+ cells (106 cells/ml) were purifi  ed from the spleens 
of C57BL/6 mice and incubated with 10 ng/ml IL-1, 10 ng/ml IL-23, or 
IL-1 and IL-23 in the presence or absence of 1 μg/ml anti-CD3. Cell lysates 
were prepared and resolved on 12% SDS-PAGE gels, transferred onto nitro-
cellulose membranes, and blocked. Membranes were incubated with anti-
bodies specifi   c for phospho-Akt and phospho-IκBα (Cell Signaling 
Technology) and β-actin (Sigma-Aldrich). After washing, the membranes 
were incubated with horseradish peroxidase–labeled secondary antibodies 
for 1 h at room temperature and developed by chemiluminescence (Lite-
Ablot; Euroclone).
Real-time PCR. CD3+ T cells (3.5 × 106 cells/ml) were stimulated with 
1 μg/ml anti-CD3 and 10 ng/ml IL-1, 10 ng/ml IL-23, or IL-1 and IL-23. 
RNA was harvested from the cells 48 h later using an RNEasy isolation kit 
(QIAGEN) followed by reverse transcription using a QuantiTect Reverse 
transcription kit (QIAGEN). Real-time PCR for the detection of IL-17 
mRNA was performed using sense and antisense primers for IL-17A 
(Mm00439619_m1; Applied Biosystems) and a FAM-labeled MGB Taqman 
probe. 18S ribosomal RNA was used as an endogenous control. Samples 
were assayed on an Applied Biosystems 7300 PCR machine.
Statistical analysis. Cytokine levels were compared by one-way ANOVA. 
Where signifi  cant diff  erences were found, the Tukey-Kramer multiple com-
parisons test was used to identify diff  erences between individual groups. 
  Signifi  cance of the results from real-time PCR was determined using 
  Newman-Keul’s test.
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